Transformative Acquisition Expected to Triple NEXGEL Revenue, Drive Immediate Profitability
Summary
NEXGEL, Inc. has signed a definitive agreement to license and acquire a transformative portfolio of commercial-stage regenerative biomaterial products from Celularity Inc. This acquisition is expected to approximately triple NEXGEL's annual revenue to about $35 million and make the company immediately profitable upon closing. The portfolio includes six established products with existing insurance reimbursement and a pipeline of three new product filings planned through 2028. Critically, an experienced commercial and scientific team is expected to join NEXGEL, significantly expanding its capabilities. This transaction represents a major strategic shift for NEXGEL, establishing it as a more substantial and profitable entity in the medical technology sector. Investors should monitor the successful closing of the transaction, which is contingent on customary processes and an anticipated $14.9 million in additional financing.
At the time of this announcement, NXGL was trading at $1.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.1M. The 52-week trading range was $0.87 to $3.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.